The Effects of Radon
“Radon is a radioactive gas you can’t see, feel, taste, or smell. It starts out as uranium, a heavy metal found in the ground and most rocks on the planet. When uranium decays, it turns into another metal called radium. When radium breaks down, it becomes radon.”

Report: 28% of West Virginia homes of high levels of cancer-causing radon gas
“CHARLESTON, W.Va. — An American Lung Association report says that high levels of radon have been detected in 28.5% of West Virginia homes. Radon is the second leading cause of lung cancer and the “State of Lung Cancer” report reveals that it is detected at high levels in 28.5% of homes in West Virginia. During January for National Radon Action Month, the American Lung Association in West Virginia urges everyone to help save lives by testing their home for radon and mitigating if high levels are detected.”

New report finds 40% of Pennsylvania homes have high levels of cancer-causing radon gas
“The American Lung Association just released its “State of Lung Cancer Report.” It reveals that about 40% of Pennsylvania homes have high levels of radon — a naturally occurring radioactive gas emitted from the ground.”

Lung Specialist Finds His “Sweet Spot” at the Intersection of Medicine and Technology
“David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.”

FDA places hold on trial of cell therapy for lung cancer after patient death
“The FDA placed a clinical hold on a trial designed to evaluate a novel cell therapy for non-small cell lung cancer after one study participant died. LN-145 (Iovance Biotherapeutics) is an autologous tumor-infiltrating lymphocyte therapy.”

FDA Issues Complete Response Letter to Sotorasib for KRAS G12C–Mutated NSCLC
“The FDA has issued a complete response letter (CRL) to the supplemental new drug application seeking the full approval of sotorasib (Lumakras) for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC).1 The FDA also issued a new postmarketing requirement (PMR) for an additional confirmatory trial to support full approval of sotorasib for this patient population. This trial will be completed by February 2028 at the latest.”